Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 8c; Cash and Cash Equivalents of $240.3M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. ARM
3. FIS
4. BROS
5. QCOM
6. EXPE
7. FSLY
8. CPAY
9. FICO
10. PAYC

Go back to Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 8c; Cash and Cash Equivalents of $240.3M

Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results

November 4, 2021 7:00 AM EDT

On-track to initiate enrollment by year-end in Phase 1b clinical trial of FTX-6058 in people with sickle cell disease

Losmapimod update planned for Q1 2022

Raised $144.2 million in gross proceeds from August 2021 public offering, extending cash runway into 2024

Conference call scheduled for 8:00 a.m. ET today

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business... More